Molecular profiling of DLBCL patients treated in the HOVON84 trial

Using a comprehensive NGS assay for simultaneous screening of mutations, copy number alterations, and translocations, 5 biology-based risk profiles could be reproduced in a Dutch DLBCL population and validated for outcome prediction. This approach will enable application as a diagnostic tool to select DLBCL patients for risk adapted treatment and help to develop biomarker-driven clinical trials for personalized medicine.EGA study EGAS00001003949

本研究采用综合性下一代测序（Next-Generation Sequencing, NGS）检测技术，同步筛查突变、拷贝数变异与染色体易位，在荷兰弥漫性大B细胞淋巴瘤（Diffuse Large B-Cell Lymphoma, DLBCL）队列中成功重现5种基于生物学特征的风险分型，并验证了其预后预测效能。该方法可作为诊断工具，用于筛选适合风险适配治疗的DLBCL患者，同时助力开发基于生物标志物的个性化医疗临床试验。本研究关联EGA项目EGAS00001003949